智翔金泰狂犬病双抗在国内报上市今日,CDE 官网显示,智翔金泰 1 类新药“斯乐韦米单抗”(研发代号:GR1801)在国内报上市。斯乐韦米单抗主要开发用于疑似狂犬病病毒 III 级暴露后的被动免疫。值得注意的是,该药也是狂犬病领域首款且目前唯一的双抗药物。斯乐韦米单抗是一款由智翔金泰自主研发的重组全人源抗狂犬病病毒(Rabies Virus, RABV)双特异性抗体。作为国内首家进入临床试验的抗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.